Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

(Reuters) -Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK in adults aged 50 years and older in a late-stage study, sending ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in ...

Moderna’s mRNA-1010 showed 26.6% higher efficacy vs. standard flu shot in adults 50+. The trial enrolled 40,805 participants across 11 countries, with mild adverse reactions reported. Tim Melvin ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19/influenza ...

Moderna said its own vaccine, dubbed mRNA-1010, had achieved a relative vaccine efficacy (rVE) of 26.6% over a “licensed standard-dose seasonal influenza vaccine” in the study of 40,805 adults ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu.. This is a ...

June 30 (Reuters) - Moderna (MRNA.O), opens new tab said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK (GSK.L), opens new tab in ...